KOP Therapeutics
ONCOLOGY PIPELINE

Four Programs.
One Modular Platform.

KOP Therapeutics is advancing a pipeline of peptide-guided ASO programs across four solid tumor indications — all built on the same TGM delivery platform, enabling capital-efficient expansion from a single validated mechanism.

All programs are in preclinical development. IND-enabling studies are the next milestone for the lead program.

PROGRAM OVERVIEW

Active Pipeline Programs

PROGRAM
INDICATION
TARGET
STAGE
PROGRESS
KOP-101
LEAD
Prostate Cancer
CCND1 / BIRC5
In Vivo PoC
KOP-102
Breast Cancer
CCND1
In Vitro
KOP-103
Brain Cancer (GBM)
CCND1
In Vitro
KOP-104
Ovarian Cancer
CCND1
In Vitro
PROGRAM DETAILS

Program-by-Program Overview

KOP-101

Prostate Cancer

Lead Program

Target: CCND1 / BIRC5

Mechanism: CCND1 / BIRC5 ASO Knockdown

Lead program. In vivo proof-of-concept completed at Charles River Laboratories. Statistically significant TGI confirmed (p=0.049). 96-hr kill study (ED50/ED90) underway at Galenvs Sciences. Next: lead & construct optimization — finalize ASO leads and conjugate design, then advance 1–2 in vivo-ready conjugates into PK/PD studies by Q1 2027.

✓

In Vitro Screen

✓

In Vivo PoC (Charles River)

3

96-hr Kill Study (ED50/ED90) — Galenvs Sciences

4

Lead & Construct Optimization + Delivery Valency Selection

5

In Vivo PK/PD Studies — Q1 2027

6

IND-Enabling Studies

KOP-102

Breast Cancer

Active

Target: CCND1

Mechanism: CCND1 ASO Knockdown

In vitro knockdown confirmed across breast cancer cell lines. CCND1 overexpression is a validated driver in ER+ and HER2+ breast cancer subtypes.

✓

In Vitro Screen

2

In Vivo PoC

3

96-hr Kill Study

4

IND-Enabling Studies

KOP-103

Brain Cancer (GBM)

Active

Target: CCND1

Mechanism: CCND1 ASO Knockdown

Glioblastoma multiforme (GBM) represents a high unmet need with limited treatment options. CCND1 overexpression is implicated in GBM proliferation and resistance.

✓

In Vitro Screen

2

In Vivo PoC

3

96-hr Kill Study

4

IND-Enabling Studies

KOP-104

Ovarian Cancer

Active

Target: CCND1

Mechanism: CCND1 ASO Knockdown

Ovarian cancer has high CCND1 expression and limited targeted therapy options. KOP's peptide carrier targets LHRH receptors overexpressed on ovarian tumor cells.

✓

In Vitro Screen

2

In Vivo PoC

3

96-hr Kill Study

4

IND-Enabling Studies

DEVELOPMENT ROADMAP

Path to IND-Enabling Studies

✓

Completed

In Vitro Validation

Up to 95% knockdown · 95 constructs screened · 4 cancer types

✓

Completed

In Vivo PoC (Charles River)

Statistically significant TGI · p=0.049 · PC3 xenograft · no observed toxicity

3

Active

96-hr Kill Study — Galenvs Sciences

ED50 / ED90 · Galenvs Sciences CRO · Montreal, QC · underway

4

Next

Lead & Construct Optimization

Finalize ASO leads · conjugate design · delivery valency selection · head-to-head uptake assay

5

Target: Q1 2027

In Vivo PK/PD Studies

1–2 in vivo-ready conjugates · PK/PD animal studies · candidate selection

6

Target

IND-Enabling Studies

GLP tox · CMC · FDA pre-IND meeting

Interested in the Pipeline?

Request our full partnering deck including pipeline details, preclinical data, and development milestones.

REQUEST PARTNERING DECK CONTACT US
KOP Therapeutics

Advancing tumor-targeted RNA therapeutics toward IND-enabling development, partnership, and commercialization.

Preclinical Stage

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation (including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP's prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited.

© 2026 KOP Therapeutics Inc. All rights reserved.

Montreal, Quebec, Canada · 604.256.9900